AMR101

DRUG2 trials

Conditions

Cardiovascular DiseasesColorectal AdenomaColorectal CancerEicosapentaenoic AcidEndoscopic SurgeryGastrointestinal Microbiome

Phase 1

PRevention Using EPA Against coloREctal Cancer

CompletedNCT04216251

Massachusetts General HospitalColorectal Adenoma, Colorectal Cancer, Eicosapentaenoic Acid +2

Start: 2020-12-09End: 2022-09-30Updated: 2024-05-03

Phase 3

A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin

CompletedNCT01492361

Amarin Pharma Inc.Cardiovascular Diseases

Start: 2011-11-30End: 2018-05-31Updated: 2022-04-14

2026-06-25

Benefit of icosapent ethyl across types and sizes of myocardial infarction in REDUCE-IT

European Journal of Preventive Cardiology2025-09-201 citations

Cardiovascular Outcomes With Icosapent Ethyl by Baseline Low‐Density Lipoprotein Cholesterol: A Secondary Analysis of the REDUCE‐IT Randomized Trial

Journal of the American Heart Association2025-02-198 citations

Cost‐Effectiveness of Icosapent Ethyl in REDUCE‐IT USA: Results From Patients Randomized in the United States

Journal of the American Heart Association2023-12-295 citations

Effectiveness of icosapent ethyl on first and total cardiovascular events in patients with metabolic syndrome, but without diabetes: REDUCE-IT MetSyn

European Heart Journal Open2023-11-0110 citations

Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials.

2023-03-06374 citations

Cardiovascular Benefits of Icosapent Ethyl in Patients With and Without Atrial Fibrillation in REDUCE‐IT

Journal of the American Heart Association2023-02-2125 citations

Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1β, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker Substudy

Circulation2022-08-01117 citations

Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior Myocardial Infarction

Journal of the American College of Cardiology2022-04-2556 citations

Impact of Icosapent Ethyl on Cardiovascular Risk Reduction in Patients With Heart Failure in REDUCE‐IT

Journal of the American Heart Association2022-04-0423 citations

Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCE‐IT PCI

Journal of the American Heart Association2022-03-0937 citations

Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL

Circulation2021-10-2865 citations

Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABG

Circulation2021-10-2855 citations

Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-IT

Journal of the American College of Cardiology2021-10-0134 citations

Reduction in Revascularization With Icosapent Ethyl

Circulation2020-11-0555 citations

REDUCE-IT USA

Circulation2019-11-11132 citations

Effects of Icosapent Ethyl on Total Ischemic Events

Journal of the American College of Cardiology2019-03-18247 citations

Icosapent Ethyl Effects on Fatty Acid Profiles in Statin-Treated Patients With High Triglycerides: The Randomized, Placebo-controlled ANCHOR Study.

2019-02-2016 citations

Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia

New England Journal of Medicine2018-11-103077 citations

Alirocumab vs usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA randomized trial.

2018-03-2364 citations

3 more papers not shown

AMR101

Sponsors

Conditions

Phase 1

Phase 3

Related Papers